Sysmex Life Science

Cost-effectiveness of liquid biopsy in colorectal cancer: Insights from Prof. Schramm Our latest article in LIQUID BIOPSY IMPACT discusses a recent health economics study with its author Prof. Wendelin Schramm, exploring the cost-effectiveness of NGS-based liquid biopsy for detecting CRC recurrence. This innovative technology holds immense promise for transforming patient care. Discover the latest insights and join the conversation!   Read more here:  https://lnkd.in/ervwYvWN #Sysmex #liquidbiopsy #colorectalcancer #cancercare 

𝗧𝗼𝗽 𝟯 𝗧𝗵𝗶𝗻𝗴𝘀 𝘁𝗼 𝗞𝗻𝗼𝘄 𝗔𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗦𝘂𝗿𝗲𝗦𝗲𝗾™ 𝗖𝗟𝗟 + 𝗖𝗡𝗩 𝗩𝟯 𝗣𝗮𝗻𝗲𝗹: 1. Enhanced gene coverage: The panel offers increased coverage for key genes like TP53, BTK, PLCG2, BCL2, and NRAS, aligning with the latest CLL research to provide a more comprehensive understanding of CLL progression. 2. High sensitivity and accuracy: The panel detects low-frequency SNVs and indels down to 1-2.5% VAF and CNVs down to 20% tumour estimation in the 5 most frequently aberrant regions, minimising the risk of missed variant calls. 3. Newly added internal reference DNA: This addition ensures accurate sample characterisation and increased lab efficiency by reducing inter-run variability. Check here for more details 👉 https://lnkd.in/e39WtpjN

💙 This #Movember, deepen your understanding of advancements in prostate cancer care. Tune in to an insightful webinar featuring Dr Cuadras and Dr Semidey, where they discuss how implementing OSNA supports patient management in prostate cancer. Gain valuable insights, and learn about the outcome of the multicentric POPCORN study, as well. Watch the webinar here: 👉 https://lnkd.in/e8P4QM58 #Sysmex

𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗦𝗵𝗶𝗻𝗶𝗻𝗴 𝗮 𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗻𝗲𝘄 𝘀𝘁𝗮𝗴𝗶𝗻𝗴 𝘁𝗲𝗰𝗵𝗻𝗶𝗾𝘂𝗲𝘀! This Lung Cancer Awareness Month, we're excited about advancements in early detection! A new study by Romano et al. explores using sentinel lymph node mapping (SLN) to improve staging for stage I non-small cell lung cancer (NSCLC). What's the main takeaway? ✅ More precise staging: This technique helps doctors pinpoint the spread of cancer more accurately. ✅ Early detection of advanced stages: It can identify small metastases missed by traditional methods, potentially leading to earlier treatment for some patients who might be upstaged to stage IIIA. ✅ Reduced surgery risks: By identifying the key lymph nodes, it could reduce the need for extensive lymph node removal, minimising surgical complications. This innovative approach could revolutionise how we stage early-stage NSCLC, leading to better surgical outcomes. Want to learn more? Check out the full study here: https://lnkd.in/exaU7bbi #Sysmex #lungcancer

Exciting news for Breast Cancer Awareness Month! Dr Alessandra Virga and Prof sara bravaccini from the IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST Srl latest publication with Plasma-SeqSensei is out! The Novel AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 NGS Assay: A Non-Invasive Tool to Monitor Resistance Mechanisms to Hormonal Therapy and CDK4/6 Inhibitors is now available!  The study used Sysmex’s Plasma-SeqSensei Breast Cancer IVD to assess the biomarkers from 16 HR+/HER2-negative breast cancer patients. The team then monitored the patients at baseline (T0) and again 3 months (T1) into treatment. Here's a sneak peek of what they discovered: Takeaway: Alterations in PIK3CA are linked to poorer PFS, aligning with recent findings in the field. Plasma-SeqSensei detected mutations in key genes, including ESR1, down to a sensitivity of 0.06%. Conclusion: Plasma-SeqSensei is easy to use and highly accurate, detecting gene alterations as low as 0.06% MAF—an essential tool for precision oncology in HR+/HER2-negative breast cancer.  👉 https://lnkd.in/ezBgr-hi #Sysmex #BreastCancer

As part of 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡, we are proud to share our partner Cerca Biotech’s interview with Professor Abeer Shaaban, where she discusses her ground-breaking work using RT-qPCR-based assessment of mRNA expression in breast cancer classification. Her research, published in Wiley Histopathology earlier this year, represents an important step forward in understanding and diagnosing breast cancer. Watch the video to hear Professor Shaaban's insights and learn more about the future of breast cancer classification. Together, for a better healthcare journey in breast cancer. #Sysmex #BreastCancerAwareness

📢 Don't miss our upcoming webinar on acute myeloid leukaemia! 📢   Join us for an insightful session on #AML, where we’ll explore the journey from clinical suspicion to disease monitoring, guided by the expertise of Professor Klaus Metzeler.    Highlights:    ● Understanding AML risk factors and symptoms  ● Navigating the diagnostic path  ● Exploring advanced treatment strategies beyond chemotherapy  ● Monitoring disease and personalising therapy 👉 https://gtly.to/iNYZ0aq4k  📅 Date: 23 September 2024 

𝗧𝗵𝗲 𝗔𝗟𝗟𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗿𝗼𝗹𝗲 𝗼𝗳 𝗜𝗩𝗗𝗥-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗖𝘆𝘁𝗼𝗖𝗲𝗹𝗹 𝗙𝗜𝗦𝗛 𝗽𝗿𝗼𝗯𝗲𝘀 🐟 The ALLTogether clinical trial aims to enhance both the survival rate and quality of life for patients with acute lymphoblastic leukaemia (#ALL). By establishing an optimised diagnostic algorithm, the trial facilitates the best treatment decisions. Learn more about this groundbreaking trial and discover how IVDR-certified CytoCell FISH probes integrate into the diagnostic process here 👉 https://lnkd.in/d2xvZpqD #Sysmex

𝗕𝗹𝗼𝗼𝗱 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗺𝗼𝗻𝘁𝗵: 𝗦𝘆𝘀𝗺𝗲𝘅’𝘀 𝗶𝗺𝗽𝗮𝗰𝘁 𝘄𝗶𝘁𝗵 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗟&𝗟 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 🩸 Sysmex offers a variety of fluorescence in situ hybridisation (FISH) probes and next-generation sequencing (NGS) solutions to support diagnosis and clinical research in haemato-oncology. Check out the: 🐟 High quality, reliable and easy-to-use #FISH probes, e.g. PML/RARA, BCR/ABL, TP53, IGH and many more, some of them IVDR-certified. 👉 https://lnkd.in/d2xvZpqD 🧬 Innovative #NGS panels* and software for AML, CLL and MPN to detect complex structural variants of key biomarkers such as CEBPA, NPM1 and FLT3-ITDs. *for research use only (RUO) #BloodCancerAwareness

🤔 Curious about the healthcare journey of leukaemia patients? 🩺 Join our live webinar with Prof. Klaus Metzeler to learn more about acute myeloid #leukaemia:    - Risk factors, symptoms and causes of #AML  - The diagnostic path  - Treatment strategies beyond chemotherapy – recent advances in the field  - Disease monitoring – treatment success and personalised therapy adaption    👉 https://gtly.to/iNYZ0aq4k  📅 Date: 23 September 2024